{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T17:47:32Z","timestamp":1782841652494,"version":"3.54.5"},"reference-count":24,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Form Res"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Many people relapse after achieving abstinence in substance use disorders. Health care providers may scan the horizon for new technologies to predict response that allow interventions to be targeted rather than routine. Currently, no such predictive technologies are available in the United Kingdom. The Subreal app is available for use in research contexts, but no clinical data specific to the app are yet available. Early health economic modeling can use data from the literature to explore characteristics essential for the new technology to be cost-effective. This information can guide developers in setting performance targets and pricing and estimating potential cost savings and\/or cost-effectiveness for health care providers.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n This study was supported by a UK industry funding body to explore the potential of digital technologies such as the Subreal app to offer cost savings or cost-effectiveness for health care providers. We explored the threshold price and clinical effectiveness required to deliver cost savings and cost-effectiveness in 2 subpopulations with substance use disorders in a UK setting.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Deterministic models were used to estimate costs per relapse and quality-adjusted life years over 1-, 5-, and 20-year time horizons for people who have achieved abstinence after treatment for alcohol or opioid misuse. The intervention was a digital technology predicting relapse, provided\u2014in addition to standard care\u2014for 1 year post achievement of abstinence. In Subreal, biomarker data are collected daily through the app, and artificial intelligence\u2013enhanced risk assessment flags patients who require additional support. The comparator was event-driven, reactive response to relapse. Costs and quality-of-life estimates were calculated using Markov models with data from existing published sources. The base-case estimate of 15% reduction in first-year relapse rates was based on a previous study on a similar but simpler digital technology.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Digital technologies such as the Subreal app have the potential to be cost-saving from a UK health and social care perspective, especially when used over a longer time horizon. Assuming a reduction of 15% in first-year relapse rates, digital technologies have the potential to be cost-saving, provided that they do not cost more than \u00a3300 (US $400.09) and \u00a3460 (US $613.47) per patient per annum for alcohol and opioid use disorders, respectively. No cost was included for postalert care, as it was assumed that this could be met within existing resources. Cost savings would be achieved predominantly through a reduction in treatment requirements as fewer people relapse. Price thresholds would reduce correspondingly if a <15% reduction in relapse rates were achieved.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Developers of digital technologies that aim to reduce relapse need to focus on the generation of evidence of clinical effectiveness and develop a commercially sustainable pricing model that allows health care providers to benefit from cost savings.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/87186","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:25:05Z","timestamp":1772137505000},"page":"e87186-e87186","source":"Crossref","is-referenced-by-count":0,"title":["Prediction of Relapse Using Digital Technology in People in Recovery From Substance Use Disorders: Early Economic Evaluation With a Case Study of the Subreal App"],"prefix":"10.2196","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4568-5483","authenticated-orcid":false,"given":"Janet","family":"Bouttell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5612-988X","authenticated-orcid":false,"given":"Micha\u0142","family":"Bartler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6098-6903","authenticated-orcid":false,"given":"Sarah","family":"Bolton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"R1","unstructured":"Adult substance misuse treatment statistics 2023 to 2024: report. Office for Health Improvement and Disparities. Nov 28, 2024. URL: https:\/\/www.gov.uk\/government\/statistics\/substance-misuse-treatment-for-adults-statistics-2023-to-2024\/adult-substance-misuse-treatment-statistics-2023-to-2024-report [Accessed 25-03-2026]"},{"issue":"9682","key":"R2","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1016\/S0140-6736(09)60746-7","article-title":"Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders","volume":"373","author":"Rehm","journal-title":"Lancet"},{"key":"R3","unstructured":"Alcohol-specific deaths in the UK: registered in 2023. Office for National Statistics. Feb 5, 2025. URL: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/causesofdeath\/bulletins\/alcoholrelateddeathsintheunitedkingdom\/registeredin2023 [Accessed 25-03-2026]"},{"key":"R4","unstructured":"Deaths related to drug poisoning in England and Wales: 2023 registrations. Office for National Statistics. Oct 23, 2024. URL: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/deaths\/bulletins\/deathsrelatedtodrugpoisoninginenglandandwales\/2023registrations [Accessed 25-03-2026]"},{"issue":"6","key":"R5","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1177\/0193841X07307771","article-title":"An eight-year perspective on the relationship between the duration of abstinence and other aspects of recovery","volume":"31","author":"Dennis","journal-title":"Eval Rev"},{"key":"R6","volume":"72","author":"Simpson","journal-title":"NIDA Res Monogr"},{"key":"R7","unstructured":"10 year health plan for England: fit for the future. NHS England. 2019. URL: https:\/\/www.england.nhs.uk\/london\/our-work\/10-year-health-plan-for-england-fit-for-the-future\/ [Accessed 25-03-2026]"},{"key":"R8","unstructured":"Core20PLUS5 (adults)\u2013an approach to reducing healthcare inequalities. NHS England. 2025. URL: https:\/\/www.england.nhs.uk\/about\/equality\/equality-hub\/national-healthcare-inequalities-improvement-programme\/core20plus5\/ [Accessed 30-03-2026]"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.3389\/fdgth.2023.1282022","article-title":"Evaluation of 6 years of eHealth data in the alcohol use disorder field indicates improved efficacy of care","volume":"5","author":"Wallden","journal-title":"Front Digit Health"},{"key":"R10","unstructured":"HTA Glossary. URL: https:\/\/htaglossary.net\/HomePage [Accessed 18-07-2025]"},{"key":"R11","unstructured":"What NICE does. National Institute for Health and Care Excellence (NICE). URL: https:\/\/www.nice.org.uk\/what-nice-does [Accessed 30-03-2025]"},{"issue":"1","key":"R12","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462325100123","article-title":"Defining early health technology assessment: building consensus using Delphi technique","volume":"41","author":"Grutters","journal-title":"Int J Technol Assess Health Care"},{"issue":"10","key":"R13","doi-asserted-by":"publisher","first-page":"575","DOI":"10.15171\/ijhpm.2019.36","article-title":"Problems and promises of health technologies: the role of early health economic modeling","volume":"8","author":"Grutters","journal-title":"Int J Health Policy Manag"},{"key":"R14","unstructured":"Glossary. National Institute for Health and Care Excellence. URL: https:\/\/www.nice.org.uk\/glossary [Accessed 18-07-2025]"},{"key":"R15","unstructured":"NICE Health Technology Evaluations: The Manual. National Institute for Health and Care Excellence (NICE); 2022. URL: https:\/\/www.nice.org.uk\/guidance\/GID-NGC10018\/documents\/642 [Accessed 22-07-2025]"},{"issue":"6","key":"R16","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1111\/dar.13257","article-title":"Examining untreated and treated alcohol problem resolution in an Australian online survey sample","volume":"40","author":"Mellor","journal-title":"Drug Alcohol Rev"},{"issue":"3","key":"R17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.6185","article-title":"Association between daily alcohol intake and risk of all-cause mortality: a systematic review and meta-analyses","volume":"6","author":"Zhao","journal-title":"JAMA Netw Open"},{"issue":"7516","key":"R18","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1136\/bmj.331.7516.541","article-title":"Effectiveness of treatment for alcohol problems: findings of the randomised UK alcohol treatment trial (UKATT)","volume":"331","author":"UKATT Research Team","journal-title":"BMJ"},{"issue":"3","key":"R19","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/00952990.2018.1545131","article-title":"A retrospective cohort study of mortality rates in patients with an opioid use disorder treated with implant naltrexone, oral methadone or sublingual buprenorphine","volume":"45","author":"Kelty","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"2","key":"R20","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10198-018-0955-5","article-title":"Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries","volume":"20","author":"Janssen","journal-title":"Eur J Health Econ"},{"key":"R21","unstructured":"Naltrexone for the Management of Opioid Dependence: Technology Appraisal Guidance 115. National Institute for Health and Care Excellence; 2007. URL: https:\/\/www.nice.org.uk\/guidance\/ta115\/resources\/naltrexone-for-the-management-of-opioid-dependence-pdf-82598074558405 [Accessed 25-03-2026]"},{"issue":"1","key":"R22","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-02204-0","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"20","author":"Husereau","journal-title":"BMC Med"},{"issue":"1","key":"R23","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1093\/alcalc\/agh236","article-title":"Cost and outcome analysis of two alcohol detoxification services","volume":"41","author":"Parrott","journal-title":"Alcohol Alcohol"},{"issue":"5","key":"R24","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1097\/MLR.0b013e3181d68859","article-title":"The effect of alcohol treatment on social costs of alcohol dependence: results from the COMBINE study","volume":"48","author":"Zarkin","journal-title":"Med Care"}],"container-title":["JMIR Formative Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/formative.jmir.org\/2026\/1\/e87186","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T17:14:40Z","timestamp":1782839680000},"score":1,"resource":{"primary":{"URL":"https:\/\/formative.jmir.org\/2026\/1\/e87186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":24,"URL":"https:\/\/doi.org\/10.2196\/87186","relation":{},"ISSN":["2561-326X"],"issn-type":[{"value":"2561-326X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"article-number":"v10i9682e87186"}}